+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The pressor effect of droperidol on a patient with pheo chromo cytoma

Anesthesiology (Hagerstown) 46(5): 359-361
The pressor effect of droperidol on a patient with pheo chromo cytoma
Although it was recommended to give phenoxybenzamine orally at the rate of 1 mg/kg per day, it was administered i.v. because prompt and reliable action was necessary when a hypertensive episode was encountered following the trial administration of droperidol. Initially, a dose of 30 mg was given. This was subsequently adjusted to the minimum amount necessary to maintain the desired blood pressure. The small dose used, 0.3 mg/kg/day, caused no side effect and was sufficient to prevent extreme hypertension during the surgical procedure. Although mild hypertension was inevitable, it was easily controlled with phentolamine. The present case made it evident that droperidol causes extreme hypertension in patients with pheochromocytoma. The site of action of droperidol is unknown. In spite of the known pressor effect of the drug in this patient, neuroleptanesthesia using droperidol was applied for the following reasons: The increase in blood pressure induced by droperidol was controllable with an .alpha.-adrenergic receptor blocker. Neuroleptanesthesia does not sensitize the heart to catecholamines as the other halogenated volatile anesthetics. It has little depressant effect on cardiac and renal functions.

Accession: 006740043

PMID: 851247

Related references

Differences between sporadic pheo chromo cytoma and pheo chromo cytoma in multiple endocrine neoplasia type 2. American Journal of Surgical Pathology 4(2): 121-126, 1980

Diagnosis and location of cushing syndrome and pheo chromo cytoma and surgical approach to pheo chromo cytoma. Nishinihon Journal of Urology 40(2): 180-184, 1978

A reevaluation of the glucagon provocative test for pheo chromo cytoma the in vitro release of catecholamine from the adrenal medulla or pheo chromo cytoma tissue and the effect of intra venous glucagon on urinary catecholamine excretion and blood pressure. Folia Endocrinologica Japonica 56(6): 885-867, 1980

Familial bilateral pheo chromo cytoma with medullary carcinoma of the thyroid the 2nd kindred of familial pheo chromo cytoma in japan. Japanese Heart Journal: 405-413, 1971

The clinical anatomy of pheo chromo cytoma 2 localization of pheo chromo cytoma. 1982

Enkephalins in pheo chromo cytoma studies in a rat model of pheo chromo cytoma. Clinical Research 31(2): 333A, 1983

Pressor response to norepinephrine infusion in patients with pheo chromo cytoma. Hiroshima Journal of Medical Sciences 32(3): 355-358, 1983

The effect of sulpiride in a patient with complications of a pheo chromo cytoma. Netherlands Journal of Medicine 24(2): 68-71, 1981

Pheo chromo cytoma and pheo chromo blastoma scintigraphic localization with iodine 131 labeled iodobenzyl guanidine. Acta Endocrinologica Supplementum 103(256): 105, 1983

Neopl extra adrenal pheo chromyo cytoma literature review and report of a neopl cervical pheo chromo cytoma man. Surgery (St Louis) 63(2): 268-279, 1968